Actuate Therapeutics(ACTU)
FORT WORTH, TXBiotechnology
Focus: Actuate Therapeutics is a public biotechnology company focused on small-molecule oncology drugs, currently advancing a Phase 2 program (9-ING-41) across eight clinical trials. The company is pre-revenue with minimal cash reserves and significant operating losses.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Actuate Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Actuate Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Elraglusib Oral Tablets
Advanced Malignant Solid TumorClinical Trials (1)
NCT07714395Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors
Phase 1/2Help build intelligence for Actuate Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.